Approval of Novartis’ Farydak (Panobinostat) for Multiple Myeloma

The Multiple Myeloma Research Foundation (MMRF) praises the Food and Drug Administration’s (FDA) decision to approve Farydak (panobinostat) for patients with advanced myeloma and treatment resistant multiple myeloma. Specifically, Farydak is approved in combination with Velcade (bortezomib) and dexamethasone for the treatment of multiple myeloma for patients who have received at least two prior standard therapies, including bortezomib and an immunomodulatory (IMiD) agent.